Biotech Q&A; BioSante Announces Completion of Enrollment in LibiGel Safety Study
Point Roberts, WA, LINCOLNSHIRE, Ill - June 7, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview and update with Mr. Stephen M. Simes, president and chief executive officer of BioSante Pharmaceuticals. Mr. Simes discusses the significance of the Company’s completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study.
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD).
BioSante Pharmaceuticals Interview
Q: Investorideas.com
Stephen, the company has announced completion of the enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. Can you explain to investors how it was determined that the current enrollment is sufficient?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes, based on the last unblinded statistical analysis by the independent statistician of the Data Monitoring Committee, it was determined that according to the FDA-agreed sample size analysis enrollment should stop, based on meeting a minimum 90 percent predictive probability of success of the safety study to show the safety of LibiGel at the primary data analysis. As per the protocol, the safety study will continue for 12 months of therapy from the last subject enrolled before the primary analysis will be conducted by BioSante, which will provide the data for BioSante's new drug application (NDA) submission anticipated to be made in 2012. The study will continue for five years.
Q: Investorideas.com
How does this impact the timeline for a new drug application (NDA) submission?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our projected timeline is to submit an NDA to the FDA seeking approval to market LibiGel by the end of 2012.
Q: Investorideas.com
Can you explain to investors the timelines and the next stages of the Phase III LibiGel safety study?
Based on the LibiGel safety study protocol, the primary analysis of data will be conducted in 12 months. This will put us in a position to submit the NDA by the end of 2012.
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Q: Investorideas.com
LibiGel is currently the only product in the world in Phase III clinical development for the treatment of HSDD- Can you explain to new investors the significance of being first to market?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We believe the potential market for products to treat women's sexual health is well over $1 billion in the U.S. alone. We also believe that LibiGel will be the first product approved for the treatment of menopausal women in this indication. Being first to market will result in gaining the majority of the available market.
Related News Release:
Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Completes Enrollment in LibiGel® Phase III Safety Study
May 31, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
BioSante has been informed by the LibiGel safety study independent Executive Committee regarding the outcome of the sample size analysis that determines the number of subjects to be enrolled in the LibiGel Phase III safety study. The FDA-agreed sample size analysis indicates that enrollment should stop, based on meeting a minimum 90 percent predictive probability of success of the safety study to show the safety of LibiGel at the primary data analysis. As per the protocol, the safety study will continue for 12 months of therapy from the last subject enrolled before the primary analysis will be conducted by BioSante, which will provide the data for BioSante's new drug application (NDA) submission anticipated to be made in 2012. The study will continue for five years.
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/05311.asp
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com azachary@mckinneychicago.com
For Media:
McKinney/Chicago
Alan Zachary
312-506-5220; azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
The full BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory:
http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com
Tuesday, June 07, 2011
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Receives First Order for the Chinese Marketplace
CENTERVILLE, MA – June 7, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that it had received its first order of ViraTech UV-400's for test and evaluation for the Chinese marketplace. The units will be manufactured to Chinese electrical standards, and will be shipped for evaluation to 3 hospitals in different Chinese cities.
"This is our first entry into the biggest potential market for our products in the world," said John Lennon, President of UV Flu. "China has approximately 330,000 hospitals, with even greater numbers of clinics, and the spread of airborne bacteria and viruses is epidemic in many areas. Children in many cities are examined before they're allowed on school grounds, and it's not uncommon to see large numbers of people in hospital waiting areas with IVs, providing a fertile environment for the airborne spread of bacteria.
"We have been patiently building our brand over the last several months, and the results are about to be realized. We now have RX-3000s in a significant number of the top hospitals in America, and are currently back-ordered, while a new program we are starting with Hotels later this month is expected to put us in a similar back-order situation on the UV Flu side. We also hope to have our new initiatives in China, along with the Mideast, introduced later this month," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
CENTERVILLE, MA – June 7, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that it had received its first order of ViraTech UV-400's for test and evaluation for the Chinese marketplace. The units will be manufactured to Chinese electrical standards, and will be shipped for evaluation to 3 hospitals in different Chinese cities.
"This is our first entry into the biggest potential market for our products in the world," said John Lennon, President of UV Flu. "China has approximately 330,000 hospitals, with even greater numbers of clinics, and the spread of airborne bacteria and viruses is epidemic in many areas. Children in many cities are examined before they're allowed on school grounds, and it's not uncommon to see large numbers of people in hospital waiting areas with IVs, providing a fertile environment for the airborne spread of bacteria.
"We have been patiently building our brand over the last several months, and the results are about to be realized. We now have RX-3000s in a significant number of the top hospitals in America, and are currently back-ordered, while a new program we are starting with Hotels later this month is expected to put us in a similar back-order situation on the UV Flu side. We also hope to have our new initiatives in China, along with the Mideast, introduced later this month," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Biotech and Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Jefferies Global Healthcare Conference
LINCOLNSHIRE, Ill. - June 7, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Phillip B. Donenberg, BioSante’s senior vice president of finance and CFO, will speak on Thursday, June 9, 2011 at 4:00pm eastern time at the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt Hotel in New York City.
Mr. Donenberg will provide an overview of BioSante, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
LINCOLNSHIRE, Ill. - June 7, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Phillip B. Donenberg, BioSante’s senior vice president of finance and CFO, will speak on Thursday, June 9, 2011 at 4:00pm eastern time at the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt Hotel in New York City.
Mr. Donenberg will provide an overview of BioSante, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
Monday, June 06, 2011
Oil and Gas Stocks News; American Petro-Hunter's (OTCBB: AAPH) North Oklahoma NOS122 Oil Well in Production
SCOTTSDALE, AZ � June 6, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is very pleased to report that the recently completed NOS122 well is undergoing production testing and appears to be a strong producer and is outperforming expectations to date.
The NOS122 well is located at the Company's North Oklahoma Project. The production test and evaluation phase has been ongoing over the past few weeks with high gravity light oil produced to the storage tank from a 6 foot pay zone. The oil cut has been steadily over 90% with some associated gas. The well has been producing oil at rates in a broad range generally between 50 and 70 barrels per day.
Although a stable daily production rate hasn't yet been established, the Company has been informed by the operator that the pay zone would benefit from a light fracture stimulation which would in all likelihood allow a significant increase in daily rates. The partners are now preparing a simple frack plan that will be implemented in the upcoming days.
The establishment of a full tank battery and ancillary production facilities is in the final stages of construction on the lease. Currently, oil in the onsite storage tank is being prepared for sale to the local purchaser and inaugural sales are expected shortly. As reported earlier, the partners have identified a minimum of 3 additional offsets to the NOS122 for future development.
Company President Robert McIntosh states, "We are very pleased at the early test results at NOS122 and to be producing oil at levels that have exceeded our expectations. The plan to stimulate the reservoir and bring on even more oil, as well as our intent to drill additional wells very shortly, is rapidly moving this leasehold into becoming a key component of our growing production portfolio."
American Petro-Hunter has a 50% working interest in the NOS122 and oil is sold to Sunoco, the regional purchaser.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
SCOTTSDALE, AZ � June 6, 2011 (Investorideas.com energy newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is very pleased to report that the recently completed NOS122 well is undergoing production testing and appears to be a strong producer and is outperforming expectations to date.
The NOS122 well is located at the Company's North Oklahoma Project. The production test and evaluation phase has been ongoing over the past few weeks with high gravity light oil produced to the storage tank from a 6 foot pay zone. The oil cut has been steadily over 90% with some associated gas. The well has been producing oil at rates in a broad range generally between 50 and 70 barrels per day.
Although a stable daily production rate hasn't yet been established, the Company has been informed by the operator that the pay zone would benefit from a light fracture stimulation which would in all likelihood allow a significant increase in daily rates. The partners are now preparing a simple frack plan that will be implemented in the upcoming days.
The establishment of a full tank battery and ancillary production facilities is in the final stages of construction on the lease. Currently, oil in the onsite storage tank is being prepared for sale to the local purchaser and inaugural sales are expected shortly. As reported earlier, the partners have identified a minimum of 3 additional offsets to the NOS122 for future development.
Company President Robert McIntosh states, "We are very pleased at the early test results at NOS122 and to be producing oil at levels that have exceeded our expectations. The plan to stimulate the reservoir and bring on even more oil, as well as our intent to drill additional wells very shortly, is rapidly moving this leasehold into becoming a key component of our growing production portfolio."
American Petro-Hunter has a 50% working interest in the NOS122 and oil is sold to Sunoco, the regional purchaser.
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) showcase energy stock on Investorideas.com and energy portals and blogs (averages two thousand per month)
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Introduces "RX Air Plus," One of the World's Most Advanced Air Purification Systems
CENTERVILLE, MA � June 6, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has commenced marketing the "RX Air Plus" Air Purification System, which the Company believes could revolutionize the air purification marketplace.
The new system may prove to be the most effective air purification system in the world today, as the "RX Air Plus" System packages the RX-3000, built by the Company's RxAir subsidiary, along with 2 ViraTech UV-400 units. The Company believes this to be the only air purification system in the world utilizing two different FDA cleared Class II Medical devices as an integrated system. RX Air Plus brings together the two technologies, which combine to kill over 99% of bacteria and other contaminants, while reducing all odors and volatile organic compounds, as well as capturing over 99.97 % of all particulates within indoor areas up to 1500 square feet in size.
"No other Company offers a system which matches the capabilities of these combined technologies," said John Lennon, President of UV Flu Technologies. "The 'RX Air Plus' offers two of the most unique and effective products in the air purification marketplace today. The two ViraTech UV-400 units utilize hi-intensity germicidal UV lamps contained within a patented cartridge, which kills organic contaminants while also breaking down odors and concentrations of VOCs. The RX-3000 is one of the finest HEPA based air purifiers, capturing over 99.97% of particulates. The quality of indoor air protected by this system is typically purer than outdoor air while never having to open a window. The Company is offering the system to new customers and distributors immediately. We also plan to approach the over 1000 customer locations already utilizing the RX-3000 as possible upgrade opportunities."
"We also believe this system is going to have numerous applications in the Mideast, where microscopic sand particles are a major issue with respect to poor indoor air quality. To this end, the Company is in talks with several companies with respect to distribution in the Mideast, and expects to have an agreement in place this quarter," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
CENTERVILLE, MA � June 6, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has commenced marketing the "RX Air Plus" Air Purification System, which the Company believes could revolutionize the air purification marketplace.
The new system may prove to be the most effective air purification system in the world today, as the "RX Air Plus" System packages the RX-3000, built by the Company's RxAir subsidiary, along with 2 ViraTech UV-400 units. The Company believes this to be the only air purification system in the world utilizing two different FDA cleared Class II Medical devices as an integrated system. RX Air Plus brings together the two technologies, which combine to kill over 99% of bacteria and other contaminants, while reducing all odors and volatile organic compounds, as well as capturing over 99.97 % of all particulates within indoor areas up to 1500 square feet in size.
"No other Company offers a system which matches the capabilities of these combined technologies," said John Lennon, President of UV Flu Technologies. "The 'RX Air Plus' offers two of the most unique and effective products in the air purification marketplace today. The two ViraTech UV-400 units utilize hi-intensity germicidal UV lamps contained within a patented cartridge, which kills organic contaminants while also breaking down odors and concentrations of VOCs. The RX-3000 is one of the finest HEPA based air purifiers, capturing over 99.97% of particulates. The quality of indoor air protected by this system is typically purer than outdoor air while never having to open a window. The Company is offering the system to new customers and distributors immediately. We also plan to approach the over 1000 customer locations already utilizing the RX-3000 as possible upgrade opportunities."
"We also believe this system is going to have numerous applications in the Mideast, where microscopic sand particles are a major issue with respect to poor indoor air quality. To this end, the Company is in talks with several companies with respect to distribution in the Mideast, and expects to have an agreement in place this quarter," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Oil and Gas Investor Alert; Osage (OTCBB: OEDV) Mississippian Formation Recoverable Reserves Data Highlights
Point Roberts, WA - June 6, 2011 (Investorideas.com Energy Newswire) - Investorideas.com, a leader in sector research including oil and gas stocks, issues a trading alert, stock chart and recoverable reserves data highlights for Osage Exploration and Development, Inc. (OTCBB: OEDV). The recoverable reserves data was prepared by Pinnacle Energy Services, LLC of Oklahoma City.
Since 2007, several operators have been drilling horizontally and completing the Mississippi formation. Based on available public information, SandRidge Energy and Chesapeake Energy have completed over 45 horizontal wells in Woods and Alfalfa Counties, with initial rates ranging up to 1250 BOPD and 3100 Mcfd. Although a distance away, the Osage prospects are approximately on strike with the Woods and Alfalfa County wells.
Excerpts highlighting recoverable reserves on the Osage acreage :
The prospects are located in Townships T16-19N, 3&4W of Logan County, Oklahoma. Pinnacle relied on geological maps, log data, and drilling and completion information provided by Osage which was supplemented by well data, production data, and other information gathered from public sources.
In summary, based on volumetric calculations, the calculated projected oil and gas recoverable volumes per 640 acre section are:
Marshall Ridge 1,043,000 bbls oil and 3,128 Mmcf natural gas
Crescent Ridge 909,000 bbls oil and 3,634 Mmcf natural gas
Cimarron Ridge 824,000 bbls oil and 4,118 Mmcf natural gas
The overall arithmetic average of the three prospects is 992,000 bbls of oil and 3.5 BCF of natural gas per section.
Osage Exploration and Development, Inc. currently owns in excess of 14 net sections, broken down thusly:
Marshall Ridge approximately 10 sections
Crescent Ridge approximately 3 sections
Cimarron Ridge approximately 1 section
The full, unabridged report done by Pinnacle Energy Services, LLC is available on the Osage Exploration website, www.osageexploration.com
Full news http://www.investorideas.com/CO/OEDV/news/2011/05021.asp
Visit the company showcase profile at Investorideas.com
http://www.investorideas.com/CO/OEDV/
Company News:
Osage (OTCBB: OEDV) Joint Ventures Its 10,000 Acre Horizontal Mississippian Nemaha Ridge Project
Full News: http://www.investorideas.com/CO/OEDV/news/2011/05261.asp
About Osage Exploration and Development, Inc. ( OTCBB: OEDV)
Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogotá, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
Follow (OTCBB: OEDV) on Twitter.com
http://twitter.com/#!/OsageOEDV
Request news and trading alerts on OEDV
http://www.investorideas.com/Resources/Newsletter.asp
Research more oil and gas stocks with the oil and gas stock directory at Investorideas.com – lists over 600 stocks including Bakken stocks
http://www.investorideas.com/OGSN/Stock_List.asp
Disclaimer: Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: OEDV is a paid advertising oil and gas company on Investorideas.com - Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA - June 6, 2011 (Investorideas.com Energy Newswire) - Investorideas.com, a leader in sector research including oil and gas stocks, issues a trading alert, stock chart and recoverable reserves data highlights for Osage Exploration and Development, Inc. (OTCBB: OEDV). The recoverable reserves data was prepared by Pinnacle Energy Services, LLC of Oklahoma City.
Since 2007, several operators have been drilling horizontally and completing the Mississippi formation. Based on available public information, SandRidge Energy and Chesapeake Energy have completed over 45 horizontal wells in Woods and Alfalfa Counties, with initial rates ranging up to 1250 BOPD and 3100 Mcfd. Although a distance away, the Osage prospects are approximately on strike with the Woods and Alfalfa County wells.
Excerpts highlighting recoverable reserves on the Osage acreage :
The prospects are located in Townships T16-19N, 3&4W of Logan County, Oklahoma. Pinnacle relied on geological maps, log data, and drilling and completion information provided by Osage which was supplemented by well data, production data, and other information gathered from public sources.
In summary, based on volumetric calculations, the calculated projected oil and gas recoverable volumes per 640 acre section are:
Marshall Ridge 1,043,000 bbls oil and 3,128 Mmcf natural gas
Crescent Ridge 909,000 bbls oil and 3,634 Mmcf natural gas
Cimarron Ridge 824,000 bbls oil and 4,118 Mmcf natural gas
The overall arithmetic average of the three prospects is 992,000 bbls of oil and 3.5 BCF of natural gas per section.
Osage Exploration and Development, Inc. currently owns in excess of 14 net sections, broken down thusly:
Marshall Ridge approximately 10 sections
Crescent Ridge approximately 3 sections
Cimarron Ridge approximately 1 section
The full, unabridged report done by Pinnacle Energy Services, LLC is available on the Osage Exploration website, www.osageexploration.com
Full news http://www.investorideas.com/CO/OEDV/news/2011/05021.asp
Visit the company showcase profile at Investorideas.com http://www.investorideas.com/CO/OEDV/
Company News:
Osage (OTCBB: OEDV) Joint Ventures Its 10,000 Acre Horizontal Mississippian Nemaha Ridge Project
Full News: http://www.investorideas.com/CO/OEDV/news/2011/05261.asp
About Osage Exploration and Development, Inc. ( OTCBB: OEDV)
Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogotá, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
Follow (OTCBB: OEDV) on Twitter.com
http://twitter.com/#!/OsageOEDV
Request news and trading alerts on OEDV
http://www.investorideas.com/Resources/Newsletter.asp
Research more oil and gas stocks with the oil and gas stock directory at Investorideas.com – lists over 600 stocks including Bakken stocks
http://www.investorideas.com/OGSN/Stock_List.asp
Disclaimer: Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: OEDV is a paid advertising oil and gas company on Investorideas.com - Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Osage Exploration and Development, Inc. (OEDV.OB) is a showcase oil and gas stock on Investorideas.com
Visit the company showcase profile at Investorideas.com
Request news and stock alerts for Osage Exploration and Development, Inc. (OEDV.OB)
Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Visit the company showcase profile at Investorideas.com
Request news and stock alerts for Osage Exploration and Development, Inc. (OEDV.OB)
Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Cloud Computing Stock News; Gar Wood Securities Initiates Coverage on GBS Enterprises (OTCBB:GBSX) With $9 Price Target
NEW YORK - June 6, 2011 (Investorideas.com cloud computing stocks newswire) � GBS Enterprises (OTCBB:GBSX), announced today that Gar Wood Securities, a full service institutional broker--dealer located in Chicago, Il, has initiated coverage and issued its Insight Equity Research Report on the Company with a Buy rating and $9 per share target price.
Gar Wood recently raised $7.55MM for GBS with warrant coverage that will result in an additional $9MM funding to the Company.
Some excerpts from the Gar Wood research report are as follows:
Key Points
This release contains statements, which may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or expectations of the Company. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that results may differ materially from such statements.
About GBS Enterprises, Inc.
GBS Enterprises (OTCBB:GBSX), is the parent company of Group Business Software which provides product and services for the IBM Lotus market. The company boasts more than 4,000 customers worldwide with more than 4 million users of their products and services. GBS has offices in New York, Boston, Atlanta, Toronto, London, Manchester, Copenhagen, and throughout Germany. Its European headquarters is in Frankfurt, Germany and North American headquarters is located in New York City. For more information please visit www.gbs.com.
Contact:
GROUP Business Software:
Marketing and Communications Contact: Michael Baum
Corporate Communications, michael.baum@us.gbs.com
GBS Enterprises:
Investor Relations Contact:
Gary MacDonald, EVP and Chief Business Development Officer
gmacdonald@gbsx.us Tel: 917-477-9509
NEW YORK - June 6, 2011 (Investorideas.com cloud computing stocks newswire) � GBS Enterprises (OTCBB:GBSX), announced today that Gar Wood Securities, a full service institutional broker--dealer located in Chicago, Il, has initiated coverage and issued its Insight Equity Research Report on the Company with a Buy rating and $9 per share target price.
Gar Wood recently raised $7.55MM for GBS with warrant coverage that will result in an additional $9MM funding to the Company.
Some excerpts from the Gar Wood research report are as follows:
Key Points
- As the largest provider of products and services to IBM's Lotus market, GBS has a long history of working with IBM. The Company is currently working with IBM to market its GROUP Live Cloud Platform and Notes Transformer.
- The Cloud Computing market was estimated to be $16.5 billion in 2009 and is predicted to increase to $55.5 billion in 2014. GBS competes in this market through its Cloud Automation Platform, which can be customized for a wide range of customers, and its software solutions which are now available in a SaaS format.
- Due to cost savings and efficiencies, it is estimated that 40% of all business applications will be delivered via the cloud by 2014. We believe GBS' Transformer software provides the only timely, cost effective method to move Lotus Notes applications to the Cloud, without having to rewrite entire applications or move away from Notes.
- We estimate the total market potential for the Transformer to be roughly $18.0 billion, of which we believe GBS's realizable market could be roughly $5.5 billion. The bulk of this potential revenue would have little cost associated, as it incurs little cost on IBM sales and primarily just programmer cost on applications it transforms.
- The Company's Transformer was awarded the CTO Award at Lotusphere in 2011, while its Cloud Platform won the IBM Bestseller Award at Lotusphere in 2011 after winning the CTO Award at the 2010 Lotusphere.
- Management has a track record of completing M&A deals that add new customers and/or technologies at low valuations. It is also working to expand its distribution channels, similar to its recent agreement with Alliance Technology Group to market to the government sector.
This release contains statements, which may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or expectations of the Company. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that results may differ materially from such statements.
About GBS Enterprises, Inc.
GBS Enterprises (OTCBB:GBSX), is the parent company of Group Business Software which provides product and services for the IBM Lotus market. The company boasts more than 4,000 customers worldwide with more than 4 million users of their products and services. GBS has offices in New York, Boston, Atlanta, Toronto, London, Manchester, Copenhagen, and throughout Germany. Its European headquarters is in Frankfurt, Germany and North American headquarters is located in New York City. For more information please visit www.gbs.com.
Contact:
GROUP Business Software:
Marketing and Communications Contact: Michael Baum
Corporate Communications, michael.baum@us.gbs.com
GBS Enterprises:
Investor Relations Contact:
Gary MacDonald, EVP and Chief Business Development Officer
gmacdonald@gbsx.us Tel: 917-477-9509
Disclosure: GBS Enterprises, Inc. (OTCBB:GBSX) is a paid showcase tech stock, cloud computing stock on Investorideas.com (April 2011 - 1500 per month by third party)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Tech Stock Trading Alert: Elephant Talk Communications (OTCBB: ETAK) -- "Securing the Mobile Cloud"
Point Roberts WA, New York, New York- June 6, 2011, Investorideas.com, a leader in sector stock research features a tech stock alert for Elephant Talk Communications (OTCBB: ETAK), an international provider of business software and services to the telecommunications and financial services industries. Shares of ETAK jumped in Thursday’s and Friday’s trading on higher than average volume.
It’s notable that ETAK reported bullish hiring news on June 2, “Elephant Talk Communications Hires HR Pro to Manage Worldwide Hiring Growth”, during the same week that US job data was significantly lower than expected.
Read news: http://finance.yahoo.com/news/Elephant-Talk-Communications-iw-3681823597.html?x=0&.v=1
Elephant Talk is one of the top recommendations in Josh Levine’s Microcap Investor Newsletter.
Highlights from Josh Levine's recent commentary on ETAK:
Levine described Elephant Talk's business model as "Securing the Mobile Cloud." He noted that Elephant Talk intends to manage the mobile cloud, or mobile Internet, to provide access to mobile networks for businesses around the global that are non-telecom, non-tech companies but have huge customer databases. Such companies do not want to invest in IT and telecom infrastructure such as antennas and spectrum, but will look to companies such as Elephant Talk to reach their customers and stakeholders, Levine said.
Levine noted that ValidSoft has advanced its business through its arrangement with Visa Europe and other financial institutions with its fraud-prevention solutions. Levine pointed out that Visa Europe and its 4,000 member banks handle 28 billion transactions a year.
ValidSoft's suite of advanced telecom-based solutions enables banks and other financial institutions to secure all transaction channels, is relatively inexpensive to implement, and is invisible to the customer while maintaining customer privacy, Levine said. ValidSoft has been awarded the European Privacy Seal, he noted.
What makes ValidSoft's solution so revolutionary is that it uses an out-of-band approach, according to Levine. This means that if you want to check or validate what is happening on one network (i.e., Internet), you need another, completely independent network (i.e., mobile) to verify what is happening on the first network.
Additionally, ValidSoft has the world's first commercially available four-factor authentication solution utilizing a single integrated platform. This guarantees a level of security that no competitor can even remotely match today, Levine said.
In pilot programs in the U.K. and Australia, ValidSoft's technology has demonstrated that it reduces transaction false positives from an industry average of 90% to virtually none, Levine said.
Levine also pointed out the significance of Elephant Talk and ValidSoft's strategy of positioning their services in the mobile cloud. As mobile phones are adopted by larger populations, especially where many "unbanked" communities rely on such a device for the transfer and receipt of funds, the mobile or smart phone will rapidly become the dominant form of electronic payment. Levine added that ValidSoft's technology also can provide security to a wide range of transactions in the mobile cloud beyond financial services to include health monitoring, among others.
For the fast-emerging arena of near-field communications (NFC) mobile payments, or the Digital Wallet, Levine said ValidSoft is ideally situated to address privacy and security issues relating to smart phones. The fact is, he said, ValidSoft's technologies were developed for this method and the company had long anticipated that NFC would be the future for transactions. The challenge was to develop a solution within the boundaries that respected the laws and regulations of privacy and data integrity. ValidSoft has succeeded in doing this due primarily to its out-of-band approach, which is now far ahead of competitors, Levine said.
About Josh Levine's MicroCap Investor:http://www.levinesmicrocapinvestor.com
Levine's MicroCap Investor delves deep into the world of small stocks to identify big winners, targeting innovative companies on the path of the new and revolutionary.
The strategy for MicroCap Investor is simple: to focus on small, innovative companies representing the best pure plays in the fast-growing waves of change in biotechnology, cleantech, and emerging IT.
Disclaimer/disclosure - http://www.levinesmicrocapinvestor.com/disclosure/
To learn more about this and the other outstanding investment opportunities in the MicroCap Investor portfolio, subscribe now.
http://www.levinesmicrocapinvestor.com/subscriptions/order/
InvestorIdeas.com is partnered with Josh Levine and MicroCap Investor as part of its mission to provide investors with research tools to explore the world of small stocks. The InvestorIdeas.com team operates this web site and manages the administration and marketing for MicroCap Investor. InvestorIdeas.com is a leading investment and industry research portal, with resources covering high-growth sectors including technology, biotech and cleantech.
Sign up at Investor Ideas for free investor stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dawn@investorideas.com or cvanzant@investorideas.com
Point Roberts WA, New York, New York- June 6, 2011, Investorideas.com, a leader in sector stock research features a tech stock alert for Elephant Talk Communications (OTCBB: ETAK), an international provider of business software and services to the telecommunications and financial services industries. Shares of ETAK jumped in Thursday’s and Friday’s trading on higher than average volume.
It’s notable that ETAK reported bullish hiring news on June 2, “Elephant Talk Communications Hires HR Pro to Manage Worldwide Hiring Growth”, during the same week that US job data was significantly lower than expected.
Read news: http://finance.yahoo.com/news/Elephant-Talk-Communications-iw-3681823597.html?x=0&.v=1
Elephant Talk is one of the top recommendations in Josh Levine’s Microcap Investor Newsletter.
Highlights from Josh Levine's recent commentary on ETAK: Levine described Elephant Talk's business model as "Securing the Mobile Cloud." He noted that Elephant Talk intends to manage the mobile cloud, or mobile Internet, to provide access to mobile networks for businesses around the global that are non-telecom, non-tech companies but have huge customer databases. Such companies do not want to invest in IT and telecom infrastructure such as antennas and spectrum, but will look to companies such as Elephant Talk to reach their customers and stakeholders, Levine said.
Levine noted that ValidSoft has advanced its business through its arrangement with Visa Europe and other financial institutions with its fraud-prevention solutions. Levine pointed out that Visa Europe and its 4,000 member banks handle 28 billion transactions a year.
ValidSoft's suite of advanced telecom-based solutions enables banks and other financial institutions to secure all transaction channels, is relatively inexpensive to implement, and is invisible to the customer while maintaining customer privacy, Levine said. ValidSoft has been awarded the European Privacy Seal, he noted.
What makes ValidSoft's solution so revolutionary is that it uses an out-of-band approach, according to Levine. This means that if you want to check or validate what is happening on one network (i.e., Internet), you need another, completely independent network (i.e., mobile) to verify what is happening on the first network.
Additionally, ValidSoft has the world's first commercially available four-factor authentication solution utilizing a single integrated platform. This guarantees a level of security that no competitor can even remotely match today, Levine said.
In pilot programs in the U.K. and Australia, ValidSoft's technology has demonstrated that it reduces transaction false positives from an industry average of 90% to virtually none, Levine said.
Levine also pointed out the significance of Elephant Talk and ValidSoft's strategy of positioning their services in the mobile cloud. As mobile phones are adopted by larger populations, especially where many "unbanked" communities rely on such a device for the transfer and receipt of funds, the mobile or smart phone will rapidly become the dominant form of electronic payment. Levine added that ValidSoft's technology also can provide security to a wide range of transactions in the mobile cloud beyond financial services to include health monitoring, among others.
For the fast-emerging arena of near-field communications (NFC) mobile payments, or the Digital Wallet, Levine said ValidSoft is ideally situated to address privacy and security issues relating to smart phones. The fact is, he said, ValidSoft's technologies were developed for this method and the company had long anticipated that NFC would be the future for transactions. The challenge was to develop a solution within the boundaries that respected the laws and regulations of privacy and data integrity. ValidSoft has succeeded in doing this due primarily to its out-of-band approach, which is now far ahead of competitors, Levine said.
About Josh Levine's MicroCap Investor:http://www.levinesmicrocapinvestor.com
Levine's MicroCap Investor delves deep into the world of small stocks to identify big winners, targeting innovative companies on the path of the new and revolutionary.
The strategy for MicroCap Investor is simple: to focus on small, innovative companies representing the best pure plays in the fast-growing waves of change in biotechnology, cleantech, and emerging IT.
Disclaimer/disclosure - http://www.levinesmicrocapinvestor.com/disclosure/
To learn more about this and the other outstanding investment opportunities in the MicroCap Investor portfolio, subscribe now.
http://www.levinesmicrocapinvestor.com/subscriptions/order/
InvestorIdeas.com is partnered with Josh Levine and MicroCap Investor as part of its mission to provide investors with research tools to explore the world of small stocks. The InvestorIdeas.com team operates this web site and manages the administration and marketing for MicroCap Investor. InvestorIdeas.com is a leading investment and industry research portal, with resources covering high-growth sectors including technology, biotech and cleantech.
Sign up at Investor Ideas for free investor stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dawn@investorideas.com or cvanzant@investorideas.com
Renewable Energy Stocks Trading Alert; EnerNOC (NasdaqGS: ENOC) One of Top NASDAQ Gainers in Morning Trading
POINT ROBERTS, Wash., June 6, 2011 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including renewable energy stocks, issues a trading alert for smart grid company, EnerNOC, Inc. (NasdaqGS: ENOC), a provider of demand response applications and services. The stock has traded as high as $18.75 in morning trading. The stock is currently trading at $17.82, up 1.61 (9.93%).
The company issued news announcing its strong support for the Order issued by the Federal Energy Regulatory Commission (FERC) on June 3, 2011 regarding the methodology for valuing demand response resources in PJM's capacity market. Full news: http://finance.yahoo.com/news/FERC-Issues-Order-Preserving-iw-980733218.html?x=0&.v=1
About EnerNOC
EnerNOC unlocks the full value of energy management for our utility and commercial, institutional, and industrial (C&I) customers by reducing real-time demand for electricity, increasing energy efficiency, improving energy supply transparency in competitive markets, and mitigating emissions. We accomplish this by delivering world-class energy management applications including DemandSMART™, comprehensive demand response; EfficiencySMART™, data-driven energy efficiency; SupplySMART™, energy price and risk management; and CarbonSMART™, enterprise carbon management. Our Network Operations Center (NOC) continuously supports these applications across thousands of C&I customer sites throughout the world. Working with more than 100 utilities and grid operators globally, we deliver energy, ancillary services, and carbon mitigation resources that provide cost-effective alternatives to investments in traditional power generation, transmission, and distribution. For more information, visit www.enernoc.com.
Investorideas.com Showcase Featured Renewable Energy Stocks and green news:http://www.investorideas.com/gi/
Research smart grid stocks and more at Investorideas.com renewable energy stock directory:
Renewable Energy Stocks Directory - Global Green and Renewable Energy Stocks Directory in PDF format includes over 1300 stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges . The directory features hyperlinks to stocks symbol(s), company’s URL and company’s description. The directory includes info and links on Alternative Energy Funds, Biogas and Ethanol Stocks, Energy Efficiency Stocks, Flywheel Stocks, Fuel Cell Stocks, Geothermal Stocks, Hydrogen Production, Micro Turbine Stocks, Solar Stocks, Smart Grid Stocks, Green Transportation, Wind Power and Wind Energy Stocks and Green Infrastructure Stocks. For investors following green stocks, this is the most comprehensive global stock directory online.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About Investorideas.com Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
POINT ROBERTS, Wash., June 6, 2011 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including renewable energy stocks, issues a trading alert for smart grid company, EnerNOC, Inc. (NasdaqGS: ENOC), a provider of demand response applications and services. The stock has traded as high as $18.75 in morning trading. The stock is currently trading at $17.82, up 1.61 (9.93%).
The company issued news announcing its strong support for the Order issued by the Federal Energy Regulatory Commission (FERC) on June 3, 2011 regarding the methodology for valuing demand response resources in PJM's capacity market. Full news: http://finance.yahoo.com/news/FERC-Issues-Order-Preserving-iw-980733218.html?x=0&.v=1
About EnerNOCEnerNOC unlocks the full value of energy management for our utility and commercial, institutional, and industrial (C&I) customers by reducing real-time demand for electricity, increasing energy efficiency, improving energy supply transparency in competitive markets, and mitigating emissions. We accomplish this by delivering world-class energy management applications including DemandSMART™, comprehensive demand response; EfficiencySMART™, data-driven energy efficiency; SupplySMART™, energy price and risk management; and CarbonSMART™, enterprise carbon management. Our Network Operations Center (NOC) continuously supports these applications across thousands of C&I customer sites throughout the world. Working with more than 100 utilities and grid operators globally, we deliver energy, ancillary services, and carbon mitigation resources that provide cost-effective alternatives to investments in traditional power generation, transmission, and distribution. For more information, visit www.enernoc.com.
Investorideas.com Showcase Featured Renewable Energy Stocks and green news:http://www.investorideas.com/gi/
Research smart grid stocks and more at Investorideas.com renewable energy stock directory:
Renewable Energy Stocks Directory - Global Green and Renewable Energy Stocks Directory in PDF format includes over 1300 stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges . The directory features hyperlinks to stocks symbol(s), company’s URL and company’s description. The directory includes info and links on Alternative Energy Funds, Biogas and Ethanol Stocks, Energy Efficiency Stocks, Flywheel Stocks, Fuel Cell Stocks, Geothermal Stocks, Hydrogen Production, Micro Turbine Stocks, Solar Stocks, Smart Grid Stocks, Green Transportation, Wind Power and Wind Energy Stocks and Green Infrastructure Stocks. For investors following green stocks, this is the most comprehensive global stock directory online.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
About Investorideas.com Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Mining and Gold Stocks News; LOMIKO (TSX-V: LMR; OTC: LMRMF) ESTABLISHES EXPLORATION CAMP AT VINES LAKE GOLD PROJECT
Vancouver - June 6, 2011 (Investorideas.com mining stocks newswire) – LOMIKO METALS INC. (TSX-V:LMR, OTC: LMRMF, Europe: ISIN: CA54163Q1028, WKN: A0Q9W7,) ("Lomiko" or "the Company) Exploration Manager Lesley Hunt has reports that Lomiko has established an exploration camp to coordinate activities related to the summer exploration program at Vines Lake. Lomiko holds the rights to three contiguous mineral tenures, totaling 1,169 Ha (2,888 Acres) located in the southwestern corner of the Cassiar Gold District or ‘Cassiar Gold Camp'. Exploration activities are to commence in June, 2011 and continue until September, 2011.
This program is designed to target both potentially high-grade gold vein systems, as seen at the adjacent Table Mountain Mine, in addition to the prospect of intrusion related mineralization. Phase I of the program is targeted to begin as soon as weather and snow conditions permit. Phase II will explore follow-up targets resulting from the geological mapping, geochemical and ground geophysical surveys resulting from Phase I.
Due to the property's close proximity to formerly producing mines with a proven history in the Cassiar Mining Camp, it is the opinion of the company that potential exists on the 100% owned Vines Lake Property for discovering new high-grade gold vein systems. Also, there is a potential for other intrusion related mineralization in proximity to the Cassiar Batholith and its associated boundary contacts, over which Lomiko's Vines Lake property claims are located.
Cassiar Area Highlights:
For more information, please contact Paul Gill at 6047295312 Email: lomiko@dccnet.com. Website: www.lomiko.com.
On behalf of Lomiko Metals Inc,
Signed: "A. Paul Gill"
A. Paul Gill, President & CEO
We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Vancouver - June 6, 2011 (Investorideas.com mining stocks newswire) – LOMIKO METALS INC. (TSX-V:LMR, OTC: LMRMF, Europe: ISIN: CA54163Q1028, WKN: A0Q9W7,) ("Lomiko" or "the Company) Exploration Manager Lesley Hunt has reports that Lomiko has established an exploration camp to coordinate activities related to the summer exploration program at Vines Lake. Lomiko holds the rights to three contiguous mineral tenures, totaling 1,169 Ha (2,888 Acres) located in the southwestern corner of the Cassiar Gold District or ‘Cassiar Gold Camp'. Exploration activities are to commence in June, 2011 and continue until September, 2011.
This program is designed to target both potentially high-grade gold vein systems, as seen at the adjacent Table Mountain Mine, in addition to the prospect of intrusion related mineralization. Phase I of the program is targeted to begin as soon as weather and snow conditions permit. Phase II will explore follow-up targets resulting from the geological mapping, geochemical and ground geophysical surveys resulting from Phase I.
Due to the property's close proximity to formerly producing mines with a proven history in the Cassiar Mining Camp, it is the opinion of the company that potential exists on the 100% owned Vines Lake Property for discovering new high-grade gold vein systems. Also, there is a potential for other intrusion related mineralization in proximity to the Cassiar Batholith and its associated boundary contacts, over which Lomiko's Vines Lake property claims are located.
Cassiar Area Highlights:
- A new company with Chinese investors known as China Minerals Mining Corporation is located adjacent to the property.
- A fully permitted 270 tonne per day, gravity and flotation mill, power plant, assay laboratory and tailings impoundment facility is owned by China Minerals.
- Approximately 316,000 ounces of gold have been produced at the adjacent Table Mountain Mine from 1979-2007 under various companies.
- Current Resource Estimates for the Table Mountain Mine are 21,471 tonnes grading 18.02 g/t indicated and 65,757 tonnes grading 24.3 g/t inferred were reported at the adjacent property in the May, 2010 NI43-101 Technical Report on the Table Mountain Property by C. Pearson and F.J. Bakker.
- Two significant anomalies have been identified by geophysical surveys.The claims cover formations of the Sylvester group, which are known to contain productive zones of gold mineralization in the area.
- The Vines Lake Property is located approximately two kilometres southwest of the former Erickson gold mine.
- Highway 37 N bisects the property north to south providing excellent access.
For more information, please contact Paul Gill at 6047295312 Email: lomiko@dccnet.com. Website: www.lomiko.com.
On behalf of Lomiko Metals Inc,
Signed: "A. Paul Gill"
A. Paul Gill, President & CEO
We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. Lomiko Metals Inc. (TSX-V: LMR) three month showcase gold stock on Investorideas.com and all related mining portals and blogs (one thousand per month)
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Biotech and Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Lifting of Clinical Hold on GVAX Prostate Cancer Vaccine
CHICAGO - June 6, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been lifted by FDA. Manufacturing of new GVAX Prostate is complete, and planning for a Phase II clinical trial at the Johns Hopkins Kimmel Cancer Center is underway.
BioSante funded the manufacturing of GVAX Prostate, and the trial will be supported in part by the Prostate Cancer Foundation. Important start-up funding for this study was provided by the OneInSix Foundation.
"The Prostate Cancer Foundation funded the early work at Johns Hopkins University that resulted in the development of the GVAX Prostate Cancer Vaccine. We are pleased to continue support of Dr. Charles Drake and his innovative clinical and laboratory investigations of GVAX at Hopkins," said Howard R. Soule, PhD, executive vice president and chief science officer of the Prostate Cancer Foundation. "We are delighted that the OneInSix Foundation has joined in support of this important prostate cancer program. Under BioSante leadership we are hopeful that GVAX Prostate will be established as a new treatment for men with advanced prostate cancer."
"We are pleased to be working with Johns Hopkins as well as the Foundations on such an important project," said Stephen M. Simes, BioSante's president and chief executive officer. "A joint effort among the various parties involved has resulted in the FDA lifting the GVAX Prostate clinical hold which is a positive step for development of a new prostate cancer vaccine and the men who may benefit. Now that the FDA has approved the first-ever therapeutic cancer vaccine, Provenge, for the treatment of prostate cancer, we have renewed confidence that GVAX Prostate can be a valuable addition to prostate cancer patient care."
Unlike the recently approved Provenge for the treatment of prostate cancer, which requires isolation of cells from the patient that are then modified to produce the vaccine which is then re-introduced into the patient, GVAX Prostate is an off-the-shelf, non-patient-specific vaccine. It is comprised of prostate cancer cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety. GVAX Prostate will be administered via intradermal injections on an outpatient basis. To date, over 1,000 patients have been treated in clinical trials with BioSante cancer vaccines for various types of cancer. Although Phase III trials in prostate cancer were discontinued in 2008, development of GVAX Prostate has been reinitiated in view of the great need among men with prostate cancer and the lessons learned using the vaccine in previous clinical trials.
In addition to GVAX Prostate, BioSante has several other cancer vaccines which are in Phase II clinical development including vaccines for leukemia, breast cancer and pancreatic cancer. Also, BioSante has applied for and received four FDA Orphan Drug designations for cancer vaccines to treat acute myeloid leukemia, chronic myeloid leukemia, pancreatic cancer and melanoma.
About the Prostate Cancer Foundation (PCF)
The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for accelerating the world's most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $450 million and provided funding to more than 1,500 researchers at nearly 200 institutions worldwide. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer. More information about the PCF can be found at www.pcf.org.
About the OneInSix Foundation
The OneInSix Foundation is so-named because one in six American men will be diagnosed with prostate cancer. This charitable organization was founded by the late Mr. Bruce Hunsicker, an attorney from Akron, Ohio who dedicated his time and effort to raising funds for prostate cancer research and awareness.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
CHICAGO - June 6, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been lifted by FDA. Manufacturing of new GVAX Prostate is complete, and planning for a Phase II clinical trial at the Johns Hopkins Kimmel Cancer Center is underway.
BioSante funded the manufacturing of GVAX Prostate, and the trial will be supported in part by the Prostate Cancer Foundation. Important start-up funding for this study was provided by the OneInSix Foundation.
"The Prostate Cancer Foundation funded the early work at Johns Hopkins University that resulted in the development of the GVAX Prostate Cancer Vaccine. We are pleased to continue support of Dr. Charles Drake and his innovative clinical and laboratory investigations of GVAX at Hopkins," said Howard R. Soule, PhD, executive vice president and chief science officer of the Prostate Cancer Foundation. "We are delighted that the OneInSix Foundation has joined in support of this important prostate cancer program. Under BioSante leadership we are hopeful that GVAX Prostate will be established as a new treatment for men with advanced prostate cancer."
"We are pleased to be working with Johns Hopkins as well as the Foundations on such an important project," said Stephen M. Simes, BioSante's president and chief executive officer. "A joint effort among the various parties involved has resulted in the FDA lifting the GVAX Prostate clinical hold which is a positive step for development of a new prostate cancer vaccine and the men who may benefit. Now that the FDA has approved the first-ever therapeutic cancer vaccine, Provenge, for the treatment of prostate cancer, we have renewed confidence that GVAX Prostate can be a valuable addition to prostate cancer patient care."
Unlike the recently approved Provenge for the treatment of prostate cancer, which requires isolation of cells from the patient that are then modified to produce the vaccine which is then re-introduced into the patient, GVAX Prostate is an off-the-shelf, non-patient-specific vaccine. It is comprised of prostate cancer cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety. GVAX Prostate will be administered via intradermal injections on an outpatient basis. To date, over 1,000 patients have been treated in clinical trials with BioSante cancer vaccines for various types of cancer. Although Phase III trials in prostate cancer were discontinued in 2008, development of GVAX Prostate has been reinitiated in view of the great need among men with prostate cancer and the lessons learned using the vaccine in previous clinical trials.
In addition to GVAX Prostate, BioSante has several other cancer vaccines which are in Phase II clinical development including vaccines for leukemia, breast cancer and pancreatic cancer. Also, BioSante has applied for and received four FDA Orphan Drug designations for cancer vaccines to treat acute myeloid leukemia, chronic myeloid leukemia, pancreatic cancer and melanoma.
About the Prostate Cancer Foundation (PCF)
The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for accelerating the world's most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $450 million and provided funding to more than 1,500 researchers at nearly 200 institutions worldwide. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer. More information about the PCF can be found at www.pcf.org.
About the OneInSix Foundation
The OneInSix Foundation is so-named because one in six American men will be diagnosed with prostate cancer. This charitable organization was founded by the late Mr. Bruce Hunsicker, an attorney from Akron, Ohio who dedicated his time and effort to raising funds for prostate cancer research and awareness.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
Friday, June 03, 2011
Wind Stocks Trading News Alert; (NasdaqGS: BWEN), (OTCBB: CWET), (CYW.F), (NYSE
: MY), (Copenhagen: VWS.CO) - Bullish Outlook Long Term for Renewables
PointRoberts , WA - June 3, 2011 - Investorideas.com, a leader in cleantech stock research, issues a wind stocks trading alert for Broadwind Energy, Inc. (NasdaqGS: BWEN) ,Clean Wind Energy Tower, Inc. (OTCBB: CWET), City Windmills, Ltd. (CYW.F) and Vestas Wind Systems (Copenhagen: VWS.CO). The outlook for renewable energy and wind energy is bullish for the long term according a report by the IPCC.
According to a report in May, 'Potential of Renewable Energy' by the Intergovernmental Panel on Climate Change (IPCC), renewable energy, "Close to 80 percent of the world‘s energy supply could be met by renewables by mid-century if backed by the right enabling public policies.”
The report also noted, "Despite global financial challenges, renewable energy capacity grew in 2009 - wind by over 30 percent; hydropower by three percent; grid-connected photovoltaics by over 50 percent; geothermal by 4 percent and solar water/heating by over 20 percent.”
More: http://srren.ipcc-wg3.de/press/content/potential-of-renewable-energy-outlined-report-by-the-intergovernmental-panel-on-climate-change
Wind Stocks Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET) Letter to Shareholders
ANNAPOLIS , MD - May 31, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc. (OTCBB: CWET) (the "Company") announced that the Company had communicated to their shareholders of record in a letter that stated: Full news: http://www.investorideas.com/CO/CWE/news/2011/05311.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET) was established to commercialize a number of proven and validated technologies and construction systems into a single large downdraft tower structure that produces abundant inexpensive electricity.
www.cleanwindenergytower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Visit the profile for City Windmills, Ltd. (CYW.F)
http://www.investorideas.com/CO/CYW
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. City Windmills, Ltd. (CYW.F) is a paid advertising client on Investorideas.com and related blogs (thirty five hundred, five thousand shares per month)
Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dawn@investorideas.com or cvanzant@investorideas.com
Point
According to a report in May, 'Potential of Renewable Energy' by the Intergovernmental Panel on Climate Change (IPCC), renewable energy, "Close to 80 percent of the world‘s energy supply could be met by renewables by mid-century if backed by the right enabling public policies.”
The report also noted, "Despite global financial challenges, renewable energy capacity grew in 2009 - wind by over 30 percent; hydropower by three percent; grid-connected photovoltaics by over 50 percent; geothermal by 4 percent and solar water/heating by over 20 percent.”
More: http://srren.ipcc-wg3.de/press/content/potential-of-renewable-energy-outlined-report-by-the-intergovernmental-panel-on-climate-change
Wind Stocks Snapshot
- Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading at $1.60, down 0.06 (3.61%) 1:28PM EDT
- Catch the Wind Ltd. (TSX-V: CTW) trading at $0.46
- China Ming Yang Wind Power Group (NYSE: MY ) trading at$6.17, down 0.72 (10.45%) 1:34PM EDT
- City Windmills, Ltd. (CYW.F) trading at $1.55
- Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.28
- Vestas Wind Systems (Copenhagen: VWS.CO ) trading at $ 153.30, down 2.90 (1.86%)
- Dow 12,188.72 -59.83 -0.49%
- Nasdaq 2,751.92 -21.39 -0.77%
- S&P 500 1,306.76 -6.18 -0.47%
- 10 Yr Bond(%) 3.0060% -0.0240
- Oil 100.10 -0.30 -0.30%
- Gold 1,542.20 +10.20 +0.67%
Clean Wind Energy Tower, Inc. (OTCBB: CWET) Letter to Shareholders
ANNAPOLIS , MD - May 31, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc. (OTCBB: CWET) (the "Company") announced that the Company had communicated to their shareholders of record in a letter that stated: Full news: http://www.investorideas.com/CO/CWE/news/2011/05311.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET) was established to commercialize a number of proven and validated technologies and construction systems into a single large downdraft tower structure that produces abundant inexpensive electricity.
www.cleanwindenergytower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Visit the profile for City Windmills, Ltd. (CYW.F)
http://www.investorideas.com/CO/CYW
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. City Windmills, Ltd. (CYW.F) is a paid advertising client on Investorideas.com and related blogs (thirty five hundred, five thousand shares per month)
Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dawn@investorideas.com or cvanzant@investorideas.com
Subscribe to:
Posts (Atom)